The role of adjuvant agents in treating fungal diseases |
| |
Authors: | Shellee A Grim Nina M Clark |
| |
Institution: | (1) Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Room 164 (M/C 886), Chicago, IL 60612, USA |
| |
Abstract: | Invasive fungal infections (IFIs) remain a significant cause of morbidity and mortality despite the recent introduction of
new antifungal medications. In this review, the available data on the use of adjuvant agents for the treatment of IFIs are
discussed. Cytokines such as interferon-γ, colony-stimulating factors, granulocyte transfusions, and the monoclonal antibody
efungumab may have in a role in the management of IFIs through augmentation of the host immune response, whereas pathogen-specific
vaccines may help prevent infection. Pentraxin 3, an acute phase protein, may assist in the prevention and treatment of aspergillosis.
Deferasirox, an iron chelator, is being investigated as an adjunctive therapy for the treatment of zygomycosis. Lactoferrin,
an ironbinding protein, appears to have activity in Candida and Aspergillus infections, and omiganan may help prevent fungal catheter-related infections. Although none of these agents are currently
approved for the treatment of IFIs, they may be involved in current and/or future treatment options when used in combination
with antifungal drugs. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|